The stock price of Oncolytics Biotech, Inc (NASDAQ: ONCY) has jumped by 8.35 compared to previous close of 0.67. Despite this, the company has seen a gain of 26.42% in its stock price over the last five trading days. prnewswire.com reported 2025-06-11 that SAN DIEGO and CALGARY, AB, June 11, 2025 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive Officer and a member of its Board of Directors. Mr. Kelly is a successful biotech executive who has proven expertise in transformative deals and corporate strategy.
Is It Worth Investing in Oncolytics Biotech, Inc (NASDAQ: ONCY) Right Now?
Moreover, the 36-month beta value for ONCY is 0.72. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ONCY is 85.98M and currently, short sellers hold a 2.62% of that float. On June 18, 2025, ONCY’s average trading volume was 643.08K shares.
ONCY’s Market Performance
The stock of Oncolytics Biotech, Inc (ONCY) has seen a 26.42% increase in the past week, with a 62.82% rise in the past month, and a 16.66% gain in the past quarter. The volatility ratio for the week is 2.13%, and the volatility levels for the past 30 days are at 9.06% for ONCY. The simple moving average for the past 20 days is 58.96% for ONCY’s stock, with a -8.42% simple moving average for the past 200 days.
Analysts’ Opinion of ONCY
Many brokerage firms have already submitted their reports for ONCY stocks, with Maxim Group repeating the rating for ONCY by listing it as a “Buy.” The predicted price for ONCY in the upcoming period, according to Maxim Group is $3 based on the research report published on October 06, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ONCY reach a price target of $15. The rating they have provided for ONCY stocks is “Buy” according to the report published on February 17th, 2021.
ONCY Trading at 43.02% from the 50-Day Moving Average
After a stumble in the market that brought ONCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.69% of loss for the given period.
Stock Fundamentals for ONCY
The total capital return value is set at -1.97. Equity return is now at value -211.24, with -115.29 for asset returns.
Based on Oncolytics Biotech, Inc (ONCY), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -18.94.
Currently, EBITDA for the company is -33.71 million with net debt to EBITDA at 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.21.
Conclusion
To wrap up, the performance of Oncolytics Biotech, Inc (ONCY) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
